Profiles of Urinary Tract Infections in General Practice
ConditionUrinary Tract Infections
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCNGE Conseil
About this trial
Urinary tract infections (UTIs) are one of the most common bacterial infections managed in general practice: they are the 2nd site of community-acquired bacterial infection after respiratory infections (4-6 million consultations per year in France).
UTIs represent 15% of total antibiotic prescriptions in France. Antibiotics recommended for UTIs, except for cystitis, are considered as "critical" (highly generating bacterial resistances). UTIs are a potential source of antibiotic resistance: often inappropriate antibiotic prescriptions, evolution of the resistance profiles of the bacteria involved, emergence of multi-resistant strains.
The first hypothesis is that there are other profiles of clinical UTI situations in general practice than typical cystitis or pyelonephritis, including intermediate forms.
The second hypothesis is that these intermediate forms of UTI are subject to longer durations of antibiotherapy, and that probable explanatory factors need to be identified.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient ≥18 years old
fever (temperature > 38°C)
chills, sweats
burning urination
Disqualifiers
None
Trial population
Adult patients consulting in general practice for suspected urinary tract infection
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
The primary outcome will be the number of homogeneous profiles of patients with UTI in general practice and their characteristics using clinico-bacteriological indicators.
The primary outcome will be the rate and the clinical-bacteriological characteristics of the identified profiles of patients with UTI in general practice
Time frame
At Day 14 after the end of the Antiobiotic treatmentSecondary outcomes
1
For general practioners' practices:
Percentage of cytobacteriological examination of urine (CBEUs) prescribed * Number and type of additional examinations prescribed * Percentage of antibiotics prescribed, therapeutic class chosen, duration (in ordinal categories), posology
Time frame
At Day 0, at Day 14 after the end of the treatment and between Day 0 and Day14 after the end of the treatment2
For short-term evolutionary trajectories:
Number of consultations (in general practice or other specialty) and reasons * Number of emergency department visits * Number of unscheduled hospitalizations related to UTI
Time frame
At Day 0, at Day 14 after the end of the treatment and between Day 0 and Day 14 after the end of the treatment3
For short-term evolutionary trajectories:
Percentage of patients with worsening, stability or recovery of their symptoms as final condition (based on clinical assessment by GPs during a consultation at day 14)
Time frame
At Day 14 after the end of the treatment4
For the factors associated with the prescription of antibiotics:
Percentage of antibiotics prescribed, Choice of antibiotic class, whether 'delayed' or immediate, duration, posology
Time frame
At Day 14 after the end of the treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov